Chordoma – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Chordoma – Drugs In Development, 2024 report and make more profitable business decisions.
Chordoma is a rare type of bone cancer that occurs in the bones of the spine or the base of the skull. It begins in cells that once made up structures in the developing embryo that then developed into the disks of the spine. Most of these cells are gone by the time of birth or soon after, but sometimes a few remain and, rarely, they can become cancerous. Chordoma happens most often in adults between 40 and 60, though it can happen at any age. Chordoma usually grows slowly. It can be difficult to treat because of proximity to the spinal cord and other important structures, such as arteries, nerves, or the brain. The diagnosis of chordoma is done through tests and procedures such as biopsy and imaging tests. Treatment options for chordoma include surgery, radiation therapy, radiosurgery, and targeted therapies.
The Chordoma drugs in development market research report provide comprehensive information on the therapeutics under development for Chordoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chordoma and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Chordoma | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 30 molecules, with 30 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Chordoma therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Chordoma pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Chordoma treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Bavarian Nordic ASBayer AG
BioMed Valley Discoveries Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Changzhou Qianhong Bio-Pharma Co Ltd
Eli Lilly and Co
EpicentRx Inc
ImmunityBio Inc
Intensity Therapeutics Inc
Ipsen SA
Jiangsu Hengrui Medicine Co Ltd
Kronos Bio Inc
Laekna Therapeutics Shanghai Co Ltd
Monopteros Therapeutics Inc
Nascent Biotech Inc
NuCana Plc
OncoTherapy Science Inc
Pfizer Inc
Redesign Science Inc
Release Therapeutics
Replimune Ltd
Shanghai Yingli Pharmaceutical Co Ltd
Simcere Pharmaceutical Group Ltd
Sorrento Therapeutics Inc
Talus Bioscience Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Chordoma reports